Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests
Ugo Giovanni Falagario(Ospedali Riuniti di Foggia), Ash Tewari(Royal Free London NHS Foundation Trust), Sonya Prasad(Massachusetts General Hospital), Luigi Cormio(University of Foggia), Alberto Martini(The University of Texas MD Anderson Cancer Center), Ardeshir R. Rastinehad(Royal Free London NHS Foundation Trust), Alp Tuna Beksaç(Cleveland Clinic), Hari Thulasidass(Icahn School of Medicine at Mount Sinai), Sara Lewis(Icahn School of Medicine at Mount Sinai), Bachir Taouli(Cornell University), Shivaram Cumarasamy(Icahn School of Medicine at Mount Sinai), Akriti Gupta(Icahn School of Medicine at Mount Sinai), Giuseppe Carrieri(University of Foggia), Qainat N. Shah(Icahn School of Medicine at Mount Sinai), Isuru Jayaratna
Cited by 34
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease
|Annals of the Rheumatic Diseases|2001|287
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
|European Urology|2025|190